| Sarah Eggers, ACNS-BC | |
|
601 E 15th St, Austin, TX 78701-1930 | |
| (512) 324-8933 | |
| Not Available |
| Full Name | Sarah Eggers |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 16 Years |
| Location | 601 E 15th St, Austin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033568365 | NPI | - | NPPES |
| 365204201 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | AP117362 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dell Seton Med Center At The University Of Tx | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Seton Family Of Doctors | 0941333280 | 663 |
News Archive
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.
Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax.
A new study shows that genetic pre-screening could reduce the number of screening tests needed to identify individuals at risk for osteoporotic fractures. Douglas P. Kiel, M.D., M.P.H., director of the Musculoskeletal Research Center in the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, is an author on the report published this month in PLOS (Public Library of Science) Medicine.
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.
› Verified 3 days ago
| Entity Name | Seton Family Of Doctors |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588997233 PECOS PAC ID: 0941333280 Enrollment ID: O20100806000260 |
News Archive
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.
Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax.
A new study shows that genetic pre-screening could reduce the number of screening tests needed to identify individuals at risk for osteoporotic fractures. Douglas P. Kiel, M.D., M.P.H., director of the Musculoskeletal Research Center in the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, is an author on the report published this month in PLOS (Public Library of Science) Medicine.
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Eggers, ACNS-BC 4616 W Howard Ln, Austin, TX 78728-6300 Ph: () - | Sarah Eggers, ACNS-BC 601 E 15th St, Austin, TX 78701-1930 Ph: (512) 324-8933 |
News Archive
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.
Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax.
A new study shows that genetic pre-screening could reduce the number of screening tests needed to identify individuals at risk for osteoporotic fractures. Douglas P. Kiel, M.D., M.P.H., director of the Musculoskeletal Research Center in the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, is an author on the report published this month in PLOS (Public Library of Science) Medicine.
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.
› Verified 3 days ago
Emily Allen Beddingfield, ACNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 7000 N Mo Pac Expy. Ste. 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Susanne Morris, AGCNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4101 James Casey St Ste 100, Austin, TX 78745 Phone: 512-447-2202 Fax: 512-447-5337 | |
Ryan Webb, Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 12731 Research Blvd Ste B200, Austin, TX 78759 Phone: 512-407-4088 | |
Mafon Fomujang, NURSE PRACTITIONER Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 2911 Medical Arts St Ste 10, Austin, TX 78705 Phone: 866-473-0663 | |
Carole L George, MSN, BC-ACNS, CDE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 6500 N Mo Pac Expy, Bldg. 3, Suite 200, Austin, TX 78731 Phone: 512-458-8400 Fax: 512-458-8593 | |
Mrs. Mary Ann Marcella Miranda, APRN, AHCNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3200 W Slaughter Ln, C/o West Oaks Rehabilitation And Healthcare Center, Austin, TX 78748 Phone: 512-992-7836 Fax: 512-364-0654 | |
Sarah Granger-glauser, RN, ACNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 711f W 38th St, Austin, TX 78705 Phone: 512-660-0195 Fax: 512-452-9171 |